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Rationale: 
 
The incidence of anal cancer in the general population has increased 
over the last 30 years although it remains a relatively rare entity. A 
number of clinical trials conducted in the 1990’s, showed that 
radiotherapy combined with chemotherapy can cure the disease in the 
majority of patients whilst preserving the anal sphincter. Trials that 
investigated chemotherapy combinations failed to improve over the 
current standard combination of mitomycin-C and 5-FU. However, as 
different radiation strategies and schedules were used in the various 
phase II and phase III trials (that primarily addressed chemotherapy 
questions), we performed a pooled analysis of the data from all 
available phase II and III trials in to identify radiotherapy related 
parameters affecting the outcome of patients with anal cancer, 
resulting in new and improved guidelines for future studies and for 
tailor-made treatment.  
Methods: A total of 13 trials (7 phase II and 6 phase III) conducted 
were identified, totaling 3227 patients recruited between 1986 and 
2010. Data from 3036 patients from 10 studies were received (94.1%). 
Of these studies, 3 were conducted before 1994 and randomized 
against radiation alone or combined with 5FU only. These studies were 
excluded from the main analysis which focuses on radiation combined 
with doublet chemotherapy (N=2033). Patients not ≤75 years, not M0, 
or T1N0 were excluded, as well as all patients treated by 
brachytherapy, those who received <40 Gy of treatment (considered 
unfit) leaving 1343 patients in the analysis. The primary endpoint is 
loco-regional control within 5 years of entry on study. Loco-regional 
failure included events of local or regional failure and the need for 
local surgery. Secondary endpoints were progression-free and overall 
survival. A cox model adjusted by patient and disease factors was 
fitted to study the impact of treatment dose and duration. Statistical 
significance is claimed at the 5% level. 
Results: The radiotherapy regimens used in the studies are described 
in Table 1. 
Two third of the 1342 patients were women; the median age was 56 
years (range: 25-75). Tumor was confined to the anal margin in 82 
patients (6.1%). The median tumor size was 4.1 cm, 64.1% of the 
patients had T. The median follow-up in the studies was 4.1years. By 
year 5, a total of 303 events of loco-regional failure were observed 
with 5-year cumulative incidence of 25.1% (95%CI: 21.9-28.3%). The 
model included effects for sex, age (in years), N stage (N+ inguinal 
nodes -, N+inguinal nodes -, N+ unknown inguinal status vs N0), tumor 
localization (anal canal vs anal margin only), tumor size in cm (within 
combinations of tumor location and N category), total dose on the 
anal canal (≤50.5 Gy vs >50.5-55Gy,  >55-59 G, >59-59.4 Gy,>59.4 Gy) 
and overall treatment time within defined dose. This model shows a 
statistically significant negative impact of tumor size (P=0.0026) and 
of prolonged overall treatment time (P=0.0126). When the overall 
treatment time is split between the duration of the gap and the 
duration of the effective treatment time only the duration of the gap 
remained statistically significant (P=0.0049) whether the effective 
duration of the treatment lost statistical significance (P=0.0786). 
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Notch signaling is a highly conserved short-range cell-cell 
communication pathway that regulates many aspects of embryonic 
development as well as cell renewal and maintenance of adult tissues. 
In humans there are 4 Notch transmembrane receptors that are 
activated by cell surface ligands on adjacent cells of the Delta and 
Jagged families. Upon ligand binding, Notch receptors are cleaved by 
g-secretase, releasing the Notch intracellular domain (NICD) that 
migrates to the nucleus and controls the expression of numerous 
genes.  
Notch is aberrantly expressed in many cancers and both activating as 
well inactivating mutations are found. Notch signaling is not only 
important for cancer cells but also required for tumor angiogenesis. 
Thus, Notch inhibition is an attractive therapeutic target as it could 
target both tumors and their microenvironment simultaneously. Drugs 
that inhibit Notch activation such as g-secretase inhibitors (GSIs) are 
currently in clinical development.  
Here I will present an introduction on the Notch signaling pathway its 
involvement in cancer development and the promises and pitfalls of 
Notch as a drug target for therapeutic intervention in cancer.  
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Risk can be defined as a possibility of harm or damage and this is 
certainly applicable to risk in radiotherapy with potential harm to 
patients or staff associated with so many of our routine procedures.  
Risk is a therefore a fact of life in radiotherapy, it cannot be 
eliminated but it can be minimized by good management.  
Management is defined in the Oxford dictionary as the process of 
dealing with or controlling people or things.  When we link the two 
together then we see that what is important is acknowledging the 
risk, identifying the areas of most significant risk, the factors 
contributing to the risk and continuously considering ways in risk can 
be minimized or eliminated – creating a safety aware culture. 
Risk management in radiotherapy has gained significant momentum in 
recent years partly as a result of the high profile incidents that have 
been reported in the media.  Patients have a right to expect high 
quality treatment delivered in a safe environment.  The negative 
publicity generated by the media articles greatly enhances fear 
amongst the general public and our patient population and we have a 
moral and ethical responsibility to actively address the risks 
associated with our discipline and to create an environment of 
openness and transparency surrounding risk and how it is managed.  
It is important to remember that most errors or incidents are minor 
but reflect a real opportunity for learning and this is the basis of 
voluntary reporting systems.  An inciden treporting system, or safety 
information system, is one way of demonstrating transparency and a 
department that puts safety as a priority and is engaged inactive 
learning.   Voluntary reporting systems exist locally, nationally 
(PRISMA in The Netherlands) and internationally  (ROSIS and the newly 
developed International Atomic Energy Agency SAFRON system). 
Integration of incident and near incident reporting systems have been 
integrated into safety management programmes in many centres.  
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